Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany
ConclusionsSecukinumab appears to be cost effective compared with other DMARDs for the treatment of active PsA in biologic-na ïve and biologic-experienced populations in Germany.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Arthritis | Autoimmune Disease | Clinical Trials | Economics | Enbrel | Germany Health | Health Insurance | Health Management | Humira | Insurance | Psoriasis | Psoriatic Arthritis | Remicade | Rheumatology | Stelara | Study